AR125219A1 - MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF - Google Patents

MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF

Info

Publication number
AR125219A1
AR125219A1 ARP220100720A ARP220100720A AR125219A1 AR 125219 A1 AR125219 A1 AR 125219A1 AR P220100720 A ARP220100720 A AR P220100720A AR P220100720 A ARP220100720 A AR P220100720A AR 125219 A1 AR125219 A1 AR 125219A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
group
sequence selected
Prior art date
Application number
ARP220100720A
Other languages
Spanish (es)
Inventor
Sergei Andreevich Ageev
Yulia Sergeevna Chernykh
Diana Aleksandrovna Kondinskaia
Valeriia Evgenevna Shigina
Dina Khaidarovna Sakharova
Mariia Anatolevna Grefenshtein
Alina Konstantinovna Stolyarova
Valery Vladimirovich Solovyev
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021107773A external-priority patent/RU2796937C2/en
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR125219A1 publication Critical patent/AR125219A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al GD2 (gangliósido GD2). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por GD2, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por GD2, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por GD2. Reivindicación 1: Un anticuerpo monoclonal aislado o un fragmento de unión al antígeno del mismo que se une específicamente al GD2 (gangliósido GD2), caracterizado por que comprende: (a) un dominio variable de la cadena pesada que comprende: (i) CDR1 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 1 o SEQ ID Nº 2, (ii) CDR2 con la secuencia aminoácida de la SEQ ID Nº 3, (iii) CDR3 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 4, SEQ ID Nº 5, SEQ ID Nº 6 o SEQ ID Nº 7; y (b) un dominio variable de la cadena ligera que comprende: (i) CDR1 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 8 o SEQ ID Nº 9, (ii) CDR2 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 10 o SEQ ID Nº 11, (iii) CDR3 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 12 o SEQ ID Nº 13.The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to GD2 (GD2 ganglioside). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing them, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating GD2-mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof for treating GD2-mediated diseases or disorders, and uses of the antibodies and other therapeutically active compounds for treating diseases or GD2-mediated disorders. Claim 1: An isolated monoclonal antibody or an antigen-binding fragment thereof that specifically binds to GD2 (GD2 ganglioside), characterized in that it comprises: (a) a heavy chain variable domain comprising: (i) CDR1 with an amino acid sequence selected from the group of SEQ ID No. 1 or SEQ ID No. 2, (ii) CDR2 with the amino acid sequence of SEQ ID No. 3, (iii) CDR3 with an amino acid sequence selected from the group of SEQ ID No. 4 , SEQ ID No. 5, SEQ ID No. 6 or SEQ ID No. 7; and (b) a light chain variable domain comprising: (i) CDR1 with an amino acid sequence selected from the group of SEQ ID No. 8 or SEQ ID No. 9, (ii) CDR2 with an amino acid sequence selected from the group of SEQ ID No. SEQ ID No. 10 or SEQ ID No. 11, (iii) CDR3 with an amino acid sequence selected from the group of SEQ ID No. 12 or SEQ ID No. 13.

ARP220100720A 2021-03-24 2022-03-25 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF AR125219A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021107773A RU2796937C2 (en) 2021-03-24 Monoclonal antibody or its antigen-binding fragment which specifically binds to gd2 (gd2 ganglioside) and its use

Publications (1)

Publication Number Publication Date
AR125219A1 true AR125219A1 (en) 2023-06-28

Family

ID=83395963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100720A AR125219A1 (en) 2021-03-24 2022-03-25 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF

Country Status (10)

Country Link
CN (1) CN117677695A (en)
AR (1) AR125219A1 (en)
CL (1) CL2023002843A1 (en)
CO (1) CO2023012549A2 (en)
CR (1) CR20230456A (en)
EC (1) ECSP23072412A (en)
MX (1) MX2023011246A (en)
TW (1) TW202304989A (en)
UY (1) UY39687A (en)
WO (1) WO2022203552A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4987484B2 (en) * 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anticancer antibodies with reduced complement binding
US9315585B2 (en) * 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
CA2903576C (en) * 2013-03-15 2021-06-08 Nai-Kong V. Cheung High affinity anti-gd2 antibodies

Also Published As

Publication number Publication date
MX2023011246A (en) 2023-10-30
TW202304989A (en) 2023-02-01
CL2023002843A1 (en) 2024-03-22
WO2022203552A1 (en) 2022-09-29
UY39687A (en) 2022-08-31
ECSP23072412A (en) 2023-10-31
CO2023012549A2 (en) 2023-10-09
CN117677695A (en) 2024-03-08
CR20230456A (en) 2023-12-13

Similar Documents

Publication Publication Date Title
AR126019A1 (en) ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
AR110017A1 (en) PD-1 ANTIBODIES AND USES OF THESE
US20220332816A1 (en) Anti-tigit antibodies
PE20181952A1 (en) ANTI-LL-33 ANTIBODIES, COMPOSITIONS, METHODS AND USES OF THE SAME
BR112020015479A2 (en) ANTICLAUDIN ANTIBODIES 18.2 AND USES OF THE SAME
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
RU2019118359A (en) ANTIBODY TO HUMAN CD73
FI3484915T3 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
JP2020529863A (en) Anti-ROR1 antibody and its preparation and usage
JP2012518425A5 (en)
PE20220763A1 (en) MATERIALS AND METHODS FOR MODULATING T-CELL-MEDIATED IMMUNITY
PE20210554A1 (en) ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
FI3515947T3 (en) Novel antibodies against factor xi and uses thereof
US20210317216A1 (en) Anti-flt3 antibodies and compositions
AR123480A1 (en) THERAPEUTIC BINDING MOLECULES
PE20231080A1 (en) ANTIBODIES THAT BIND CD3 AND CD19
PE20230464A1 (en) BINDING OF MULTI-SPECIFIC ANTIBODIES TO BCMA
AR124084A1 (en) HEAVY CHAIN ANTIBODIES THAT BIND THE α-FOLATE RECEPTOR
RU2019134462A (en) ANTIBODIES BINDING WITH STEAP-1
PE20240895A1 (en) ANTITRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
RU2016141285A (en) BSPECIFIC ANTI-BINDING POLYPEPTIDES
AR125219A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF
AR125040A1 (en) ANTI-VISION CONSTRUCTS AND THEIR USES
CA3103169A1 (en) Materials and methods for treating stress-related disorders and cancer
AR127271A1 (en) BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND CD20, AND USES THEREOF